A Japanese pharmaceutical company has said the controversial drug Ivermectin shows an 'antiviral effect' against Omicron and other Covid-19 coronavirus variants in joint non-clinical research.
Kowa Co Ltd, which has been working with the Kitasato University in Tokyo on testing the drug, has not provided further details.
The news was reported by Reuters, which misstated that ivermectin was 'effective' against Omicron in Phase III clinical trials, which are conducted in humans.